Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 53, Issue 3, 2002, Pages 588-594

  Kwok, Young ^a   DiBiase, Steven J ^a   Amin, Pradip P ^a   Naslund, Michael ^a   Sklar, Geoffrey ^a   Jacobs, Stephen C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

125I; Brachytherapy; Prostate cancer; Risk group

Indexed keywords

ANTIGENS; BIOCHEMISTRY; HORMONES; RADIOTHERAPY; TUMORS;

PROSTATE-SPECIFIC ANTIGENS;

ONCOLOGY;

IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RADIATION DOSE; RISK ASSESSMENT; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036644218     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02796-7     Document Type: Article

References (38)

1. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: A structured debate
2. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions
3. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer
4. 125I brachytherapy
5. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma
6. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution
7. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
8. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation
9. Modern prostate brachytherapy
10. Palladium-103 brachytherapy for prostate carcinoma
11. Dose escalation with three-dimensional conformal radiation therapy affects outcome in prostate cancer
12. Prostate specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control
13. Disease-free survival after external beam irradiation and palladium-103 brachytherapy boost for high-risk prostatic carcinoma
14. Seed spacing nomogram for interstitial implants of I-125 seeds
15. Guidelines for PSA following radiation therapy
16. Nonparametric estimation from incomplete observations
17. The durability of PSA failure-free survival from 5 years to 13 years following radiotherapy in patients with localized prostate cancer
18. Radiation therapy for clinically localized prostate cancer
19. Modern prostate brachytherapy: Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
20. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases
21. 103Pd-based radiation for prostatic carcinoma
22. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy
23. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer
24. 125I prostate implant followed by external-beam radiation
25. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: A multi-institutional update
26. The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy
27. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma
28. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance
29. A dose-response study for I-125 prostate implants
30. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy
31. The role of external radiotherapy and permanent prostate brachytherapy in low and intermediate risk patients with localized prostate cancer
32. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution
33. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials
34. High dose combination radiotherapy for the treatment of localized prostate cancer
35. Quality of life outcomes after brachytherapy for early stage prostate cancer
36. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation